Glaukos Corporation (GKOS) News
Filter GKOS News Items
GKOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GKOS News Highlights
- GKOS's 30 day story count now stands at 9.
- Over the past 9 days, the trend for GKOS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, EYE and TR are the most mentioned tickers in articles about GKOS.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos Corp President & COO Joseph Gilliam Sells 25,000 SharesJoseph Gilliam, President & COO of Glaukos Corp (NYSE:GKOS), executed a sale of 25,000 shares in the company on December 21, 2023, according to a SEC Filing. |
Glaukos Announces Participation in the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., December 20, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA. |
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma TreatmentThe FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health. |
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent. |
Glaukos wins FDA approval for drug-releasing eye implant to treat glaucomaWilliam Blair analysts said the product “should revolutionize how glaucoma is treated by addressing noncompliance with drops.” |
Dow Extends Rally As Treasury Yields TankThe Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision. |
Here's Why You Should Retain Glaukos (GKOS) Stock for NowGlaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. |
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)ALISO VIEJO, Calif., December 14, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (I |
Glaukos (NYSE:GKOS) shareholders have earned a 37% return over the last yearWhile Glaukos Corporation ( NYSE:GKOS ) shareholders are probably generally happy, the stock hasn't had particularly... |
Bearish Bets: 3 Stocks You Definitely Should Think About Shorting This WeekUsing technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. PriceSmart Inc. recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings. |